ArticleBMC ophthalmology2025
Is the C reactive protein/albumin ratio a good tool for retinal vein occlusion?
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline predictors of visual response and treatment burden after ranibizumab therapy in macular edema secondary to retinal vein occlusion.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLocal and systemic inflammation may play a role in the development of retinal vein occlusion (RVO). The C-reactive protein (CRP)/albumin ratio is a useful prognostic indicator in various systemic inflammatory conditions. The aim of this study was to evaluate the levels of systemic blood markers of inflammation, including CRP/albumin ratio, in RVO.
methodsThe files of patients diagnosed with RVO were retrospectively reviewed. Thirty-four patients with RVO and 34 age- and sex-matched controls were included in the study. The control group consisted of age- and sex-matched subjects who visited the ophthalmology outpatient clinic for a routine eye examination. C-reactive protein (CRP) levels, albumin levels, and neutrophil, lymphocyte, monocyte, and platelet counts were recorded. The CRP/albumin ratio, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated.
resultsThe mean age of group 1 was 58.73 ± 12.61, and group 2 was 59.17 ± 9.93 (p = 0.873). The female/male ratio was 18/16 in group 1 and 12/22 in group 2 (p = 0.111). CRP/Albumin ratio was 0.57 ± 0.40 in group 1, 0.36 ± 0.33 in group 2 (p = 0.020). The CRP/albumin ratio was significantly higher in the patients with RVO as compared with that in the controls. A significant correlation was found between the CRP/albumin ratio and visual acuity (LogMAR) (r = 0.356, p = 0.003). According to a receiver operator characteristic (ROC) curve analysis, the cut-off value of the CRP/albumin ratio for RVO was 0.42, with sensitivity of 79% and specificity of 55%. A significant correlation was found between the CRP/albumin ratio and visual acuity. There was no significant difference between the two groups in terms of the NLR, PLR, and SII.
conclusionThe CRP/albumin ratio is a better inflammation marker than the NLR, PLR, and SII in RVO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.